The technic to pass through the blood-brain barrier is provided. A conjugate comprising: (1) a peptide that binds to a transferrin receptor, wherein the peptide is: (i) a peptide comprising 1st to 15th amino acid sequence (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Arg-Arg-Tyr-MeY-Cys) of an amino acid sequence described in SEQ ID NO: 1; (ii) a peptide comprising an amino acid sequence having substitution, deletion, addition and/or insertion of 1 to 11 amino acid residues in the 1st to 15th amino acid sequence of the amino acid sequence described in SEQ ID NO: 1; (iii) a peptide comprising 1st to 12th amino acid sequence (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys) of an amino acid sequence described in SEQ ID NO: 14; or (iv) a peptide comprising an amino acid sequence having substitution, deletion, addition and/or insertion of 1 to 8 amino acid residues in the 1st to 10th amino acid sequence of the amino acid sequence described in SEQ ID NO: 14, and (2) a compound comprising an antibody or an antigen-binding fragment thereof.

Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

The present disclosure relates to a blood-brain barrier permeable fusion protein and uses thereof, and provides a blood-brain barrier permeable fusion protein, a polynucleotide encoding the fusion protein, a vector including the polynucleotide, a transfection cell line transfected with the vector, and a pharmaceutical composition for preventing or treating diseases associated with brain dysfunction, including the fusion protein as an active ingredient.

Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

A recombinant lentiviral vector genome comprising a polynucleotide encoding a fusion polypeptide, wherein said fusion polypeptide comprises, arranged from N-terminal to C-terminal ends: a first polypeptide comprising (i) an MHC-ll-associated light invariant chain (li), or (ii)) the transmembrane domain of the transferrin receptor (TfR) and at least one antigenic polypeptide of a pathogen. The invention also relates to a lentiviral vector and pharmaceutical compositions comprising it.

Provided herein are transferrin receptor-binding domains, polypeptides comprising a transferrin receptor-binding domain, and antibodies and antibody fragments comprising a transferrin receptor-binding domain, and uses of the same.

Described herein are peptide oligonucleotide complexes comprising peptides and variants thereof as well as conjugated to, linked to, or fused to agents, wherein the peptide oligonucleotide complexes are capable of binding TfR and that are capable of modulating RNA or proteins in or on cells. Binding of a peptide oligonucleotide complex as described herein to TfR can enable transcytosis of complexes across an endothelial layer, e.g., the blood brain barrier, or the crossing of a cell membrane, such as by endocytosis. Pharmaceutical compositions and uses of such peptide oligonucleotide complexes, as well as methods of designing and manufacturing such peptide oligonucleotide complexes, to treat a disease or condition are also described herein.